Recombinant human alkaline phosphatase - AMRIF/CEVEC

Drug Profile

Recombinant human alkaline phosphatase - AMRIF/CEVEC

Alternative Names: hRESCAP; Recombinant human placental alkaline phosphatase; rhuAP; rhuAP-CAP cell; Theraptech project

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alloksys Life Sciences; CEVEC Pharmaceuticals
  • Developer AMRIF; CEVEC Pharmaceuticals
  • Class Phosphoric monoester hydrolases; Recombinant proteins
  • Mechanism of Action Cytokine modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Netherlands (Parenteral)
  • 13 Jan 2014 Recombinant human alkaline phosphatase - AMRIF/CEVEC is available for licensing.
  • 23 Oct 2013 AMRIF completes phase I trials in Rheumatoid arthritis (NCT01889147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top